New drug duo tested for Tough-to-Treat cervical cancer
NCT ID NCT06266338
Summary
This study is testing whether a combination of two existing drugs, pembrolizumab and lenvatinib, can help slow tumor growth in women with advanced cervical cancer that has returned or spread. The trial is for up to 30 women whose cancer has progressed despite prior treatments, including other immunotherapies. The goal is to see if this combination is safe and effective for controlling the disease.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CERVICAL CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
UT Southwestern Medical Center
RECRUITINGDallas, Texas, 75390, United States
Contact Email: •••••@•••••
Contact Phone: •••-•••-••••
Conditions
Explore the condition pages connected to this study.